A pharmaceutical factory can make the right thing and still have a problem: proving how it was made. Materials arrive. Someone checks them. Someone releases them. Somewhere between the warehouse and production, information has to travel with the goods. For Archimedis Digital, those handoffs are a business.
- The product: eCapsule, an ERP built around life sciences manufacturing.
- The customer: drugmakers, biotech firms, medical device businesses and their technology teams.
- The wager: factory knowledge makes software more useful, especially when every step needs evidence.
Its origin matters. In 2015, Archimedis Healthcare, the group’s pharmaceutical business, established a digital division. The company’s history records an open-source ERP deployment with GxP controls in 2016. GxP is shorthand for the good-practice requirements surrounding regulated work. Before there was a separate technology company, there was a manufacturing problem to solve.
Archimedis Digital Private Limited was incorporated in 2022. Founder and CEO Duraisamy Rajan Palani describes the connection neatly: Life Sciences is our DNA.
The company says feedback from clients and auditors encouraged it to take its digital capabilities to other life sciences firms. The factory had supplied both the problem and the first design brief.
The handoff is the product
eCapsule is built on Frappe, an open-source framework. Its modules reach across purchasing, accounting, human resources, quality, manufacturing and dispensing. The attraction is the relationship between them. A purchasing decision, a stock record and a production requirement can belong to the same working environment, rather than becoming three separate requests for information.
The quality module includes sampling and quarantine testing; manufacturing includes production planning and work orders. These are specific, unglamorous activities. They are also where a general promise to “go digital” becomes something a plant employee can actually use. The company sells the prospect of connected operations with life sciences requirements already considered in the design.
A 2022 case study gives that proposition some texture. A formulation R&D business was struggling with manual processes that, Archimedis says, delayed development and registration work. The response began with incoming materials and dispensing. The team deployed a test platform, revised it through several rounds of client feedback, trained employees and established support before expanding it.
There is a useful lesson in that sequence. Start with a piece of work that people recognize. Let them try it. Change the system around what they learn. A factory does not become digital because someone has purchased an impressive collection of screens.
The software needs a witness
Another manufacturer engagement makes the delivery work explicit. Archimedis assessed requirements, customized eCapsule and carried out installation and operational qualification. The client performed production qualification with assistance from Archimedis. Users then received training and support. The implementation had to demonstrate that the software fitted the operating process.
That explains the breadth of the services business: cloud engineering, DevOps, cybersecurity, analytics, testing, validation, packaged software implementation and helpdesk support. A customer can commission a defined project or work with the firm over a longer period. Software configuration is one part of the relationship; keeping people productive after launch supplies another.
For a buyer, this changes the budgeting question. The work described in these implementations includes requirements analysis, configuration, testing, qualification, training and support. Each belongs in the project plan. Treating the purchase as a software fee alone would leave out much of what makes the installation usable. The sensible conversation starts with which workflows will change, who owns them and what evidence will establish that they work.
For a medical device SaaS customer, the starting problem was scattered data and weak visibility into metadata. Archimedis describes an offshore team that mapped sources, validated data, developed analytics and established governance. The team eventually served as both development center and helpdesk. The assignment followed the customer’s operational needs beyond the initial build.
“Life Sciences is our DNA.”Duraisamy Rajan Palani · Founder & CEO
Its competitive position sits between enterprise software and specialist delivery. Buyers can assemble a general ERP and an implementation partner, build internally, or hire a broader technology services firm. Archimedis offers a narrower industry focus with several delivery capabilities under one roof. The useful comparison is how much translation a particular project needs between software engineers, plant staff and quality specialists.
AI inherits the same paperwork
The newer offerings extend that specialization. Lizy AI is a portfolio of agents intended for work such as document review, document generation, risk analysis and test-script preparation. These are proposed applications of AI to the recurring quality workload. Their usefulness depends on the records, requirements and review practices surrounding them.
In November 2024, Hexaware and Archimedis announced Quality & Compliance as a Solution. The offering combines risk-based assurance principles with AI-assisted work including documentation, risk analysis and quality reviews. It takes the company’s domain knowledge into a joint service offering with a larger technology provider.
In April 2026, Archimedis announced expansion of its AI Centre of Excellence in Tiruchirappalli. Reporting put its workforce at roughly 250-300 and described a plan to double it over twelve months. In May, the company announced NVIDIA Connect Program membership and a $2 million AI investment commitment. Those are expansion plans and a spending commitment, rather than evidence of completed hiring or a financing round.
Committed to AI development. An investment plan, with delivery still to prove.
A lesson worth borrowing
Archimedis’s published AI principles emphasize data integrity, interpretable outputs, human review, secure infrastructure and continued monitoring. The implication is practical: unreliable records and an unowned review process can undermine the cleverest model. A buyer needs people who can judge the output and a process for acting when it is wrong.
The same attention to people appears in Yetram Foundation’s described twelve-week residential scholarship for financially challenged students. Training covers problem-solving, teamwork and communication. For a business whose implementations depend on people changing how they work, those skills belong close to the technology.
That is also a useful limit on the proposition. An organization needs time for its own specialists to test, review and adopt the system. The manufacturer case assigns qualification work to the client as well as the supplier. Buying outside expertise still leaves decisions inside the plant.
The transferable idea is modest enough to try: pick one consequential handoff, understand its evidence requirements, involve the people doing the work and expand the validated pieces. Archimedis’s story begins where that advice belongs: inside the factory, with something that needs doing.